Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Will Not Settle Zyprexa Overpricing Suit; Judge Finds Evidence Of Fraud

Executive Summary

Lilly intends to fight rather than settle a suit by third party payers alleging the company overpriced its antipsychotic drugZyprexa (olanzapine)

You may also be interested in...



Third-Party Payers Have No Class: Zyprexa Ruling Cites Non-Uniform Pricing In Tossing Out Group Challenge

Third-party payers had hoped to obtain billions in damages in a suit claiming Eli Lilly & Co. misrepresented the side effects and safety of its antipsychotic Zyprexa (olanzapine). But an appeals court reversed their class certification and also found that they could not proceed with their main theory of damages as individual plaintiffs.

Third-Party Payers Have No Class: Zyprexa Ruling Cites Non-Uniform Pricing In Tossing Out Group Challenge

Third-party payers had hoped to obtain billions in damages in a suit claiming Eli Lilly & Co. misrepresented the side effects and safety of its antipsychotic Zyprexa (olanzapine). But an appeals court reversed their class certification and also found that they could not proceed with their main theory of damages as individual plaintiffs.

Lilly Wins Victory In Mississippi Zyprexa Case; Judge Says "Aggregate Proof" Of Liability Is Insufficient For Determining Fines

A federal judge has tossed out most of Mississippi's lawsuit against Lilly over Zyprexa marketing and rebuked the state for seeking excessive penalties

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel